Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6311
Peer-review started: July 10, 2023
First decision: July 23, 2023
Revised: August 11, 2023
Article in press: August 11, 2023
Published online: September 16, 2023
Processing time: 59 Days and 23.7 Hours
For children with abdominal Henoch-Schonlein purpura presenting abdominal pain as an initial symptom and severe clinical manifestations, but without purpura appearance on the skin, the diagnosis and treatment are relatively difficult. This study summarized the characteristics of this group of patients by literature review and provided additional references for further refinement of glucocorticoid therapy in this vasculitis.
A 6-year-old girl presented mainly with repeated abdominal pain and had received short-term out-of-hospital treatment with hydrocortisone. On day 7 after onset, gastroscopy revealed chronic non-atrophic gastritis and erosive duodenitis without purpuric rash, and no obvious resolution of the abdominal pain was found after treatment against infection and for protection of gastric mucosa. On day 14 the inflammatory indices continued to rise and the pain was relieved after enhanced anti-infective therapy, but without complete resolution. On day 19, the patient presented with aggravated abdominal pain with purplish-red dots on the lower limbs, by which Henoch-Schonlein purpura was confirmed. After 5 d of sequential treatment with methylprednisolone and prednisone, abdominal pain disappeared and she was discharged.
Henoch-Schonlein purpura-related rash may appear after long-term abdominal pain, and should be distinguished from acute and chronic gastrointestinal diseases at the early stage without typical rash. For bacterial infection-induced Henoch-Schonlein purpura, glucocorticoid therapy alone without clearing the infection may not relieve symptoms.
Core Tip: Henoch-Schonlein purpura (HSP) is a common vasculitis in children. Abdominal pain is one of its characteristic features, but the presence of gastrointestinal symptoms alone without a rash is easily misdiagnosed. We report a case of HSP with abdominal pain as the first symptom, emphasizing the importance of differential diagnosis to avoid incorrect surgery.
- Citation: Guo H, Wang ZL, Tao Z. Delayed diagnosis of abdominal Henoch-Schonlein purpura in children: A case report. World J Clin Cases 2023; 11(26): 6311-6317
- URL: https://www.wjgnet.com/2307-8960/full/v11/i26/6311.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i26.6311
Henoch-Schonlein purpura (HSP) is one of the most common vasculitis in childhood. The main pathogenesis is leukocytoclastic vasculitis and deposition of immunoglobulin A (IgA) immune complexes in small blood vessels[1]. HSP can affect the skin, joints, gastrointestinal tract, and kidney, with skin purpura as the initial symptom in most cases. Abdominal pain is a common symptom of HSP, mostly manifesting after rash[2]. EULAR/PRINTO/PRES 2008 proposed the diagnostic criteria for HSP as palpable purpura or petechia containing at least one of the following four conditions: (1) Acute diffuse abdominal pain; (2) leukocytoclastic vasculitis with IgA deposition revealed by biopsy; (3) arthritis or joint pain; and (4) renal involvement, including proteinuria or hematuria[3]. The rash usually appears on the compressed sites, especially the lower limbs and hip, but is not associated with thrombocytopenia.
Abdominal pain is a common symptom of HSP that presents mostly after the rash and rarely precedes it. Here, we highlighted an unusual case of a pediatric HSP patient with purpuric rash emerging after 19 d of persistent abdominal pain. Given the difficulty of making a clear diagnosis at the early stage when only abdominal pain without rash is present, a misdiagnosis of, for example, surgical acute abdomen or even a recommendation for surgery can result, bringing further pain and anxiety to children. To reduce the misdiagnosis rate of abdominal HSP and increase the clinical diagnostic accuracy, this study analyzed the clinical characteristics of this child in detail and summarized the characteristics of children with delayed abdominal HSP from reports that included a sample size of more than 50 cases published from 2000 to 2022.
A 6-year-old girl presented with intermittent abdominal pain and vomiting for 10 d.
Symptoms started 10 d before presentation with persistent dull pain around the umbilicus and upper abdomen, and non-ejective vomiting (gastric contents) 7-8 times a day with no coffee-like or bloody substances. There were no known sick contacts and no recent travel. The patient was seen at the local hospital and given hydrocortisone, 5 mg/kg/d and cefotaxime, 300 mg/kg/d for 6 d with no obvious remission. Gastroscopy on day 7 revealed chronic non-atrophic gastritis, hyperemia, and edema in the descending mucosa of the duodenum (Figure 1A).
Her past medical history was unremarkable.
Family history for gastrointestinal diseases or HSP was negative.
On physical examination there was periumbilical tenderness, but no other abnormalities were found. There was no hepatomegaly or splenomegaly; Blumberg and Murphy signs were negative. There was no skin rash at admission.
Blood tests showed increased inflammation indicators and platelets [white blood cells (WBC) 25.6 × 109/L, neutrophils (N) 81.7%, lymphocytes (L) 11.7%, C-reactive protein (CRP) 38 mg/L, platelets (PLT) 648 × 109/L]. Erythrocyte sedimentation rate, procalcitonin, transaminases, total and direct bilirubin, amylase, lipase, coagulation profile were within normal range. Stool culture, testing for rotavirus, adenovirus, aerobic bacteria, clostridium difficilis toxin and antigen were negative. Hemoccult was negative on three stools specimens. Urinalysis showed increased 24-h urine protein quantification (0.37 g/24 h) and α1- macroglobulin (6.01 mg/dL) Anti-Saccharomyces cerevisiae antibodies and anti-neutrophil cytoplasmic antibodies, were performed in the workout for inflammatory bowel diseases and resulted negative. Anti-nuclear antibody profile (anti-ds-DNA antibody, anti-SS-A antibody, anti-Ro52 antibody, anti-SS-B antibody, etc.) was negative to differentiate from systemic lupus erythematosus. On the other hand, in the immunological laboratory tests (IgG, IgA, IgM levels, IgG subclasses, and lymphocyte subpopulations), the level of IgA is elevated, while the other levels are normal.
An abdominal ultrasound scan showed no intussusception or appendiceal swelling. Abdominal computed tomography (CT) revealed obvious swelling in the wall of the segmental small intestine, peritonitis, and abdominal pelvic effusion.
Combined with the results of gastroscopy in another hospital, the diagnosis was as follows: (1) Acute peritonitis; and (2) chronic non-atrophic gastritis. The diagnosis of HSP was confirmed.
No improvement in abdominal pain after anti-infective treatment with cefoperazone+tazobactam and protection of gastric mucosa with omeprazole and aluminum sulfate gel for 4 d. On day 14 after onset, inflammatory indicators continued to rise (WBC 31.4 × 109/L, N 86.8%, L 8.1%, CRP 75 mg/L upon routine blood examination). After 3 d of intensive anti-infection treatment with meropenem instead of antibiotics, abdominal pain was significantly relieved but did not completely resolve. Gastroscopy on day 17 after onset revealed chronic non-atrophic gastritis and erosive duodenitis (Figure 1B), and mild to moderate chronic inflammation in the mucosa with erosion, without indication of hemorrhagic rash in the gastric mucosa. On day 19 after onset, the abdominal pain was further aggravated by paroxysmal dull pain around the umbilicus, and purplish-red hemorrhagic dots appeared on the skin mainly on the lower limbs, without pruritus, bleeding, or ulceration (Figure 1C). Platelet count was normal.
After treatment with methylprednisolone, 2 mg/kg/d for 3 d and sequential oral prednisone, 0.75 mg/kg/d for 2 d.
The abdominal pain disappeared. Laboratory tests returned to normal: WBC 9.1 × 109/L, neutrophils (N) 40.1%, lymphocytes (L) 52.6%, CRP 4.0 mg/L. No abnormalities on fecal examination and urine analysis. The patient made a full recovery and was discharged. She continued to take prednisone, 0.5 mg/kg/d for a further 2 wk. There was no recurrence over 6 mo of follow-up.
HSP, also called immunoglobulin A vasculitis, characterized by generalized aseptic inflammation of small blood vessels as a pathological basis, is the most common vasculitis in childhood. The main clinical manifestations include skin purpura, abdominal pain and gastrointestinal hemorrhage, joint swelling and pain, and renal involvement. Rash and abdominal pain are the most common symptoms. Gastrointestinal symptoms, reported in 50%–85% of HSP patients, are possibly attributed as secondary to edema and hemorrhage in the gastrointestinal wall and mesentery, and include nausea and vomiting, vomiting of blood, and bloody stools. Among these gastrointestinal symptoms, 14%–36% occur before the rash appears[4]. We performed retrospective analysis of the literature published between 2000 and 2022 with delayed abdominal HSP with a sample size of more than 50 children in Table 1. In previous studies, the interval between abdominal pain and rash in HSP patients was reported as usually 2–10 d[5,6], the longest interval in patients without glucocorticoids being 28 d and the shortest interval 1 d[7-9]. In 2006, Sato et al[10] reported an elderly HSP patient with emergence of rash after 75 d of abdominal pain, but this patient was diagnosed with pancreatitis at an early stage. Thus, it could not be excluded that the early abdominal pain was caused by pancreatitis.
Ref. | Calvo-Río et al[5] | Ji[19] | Chao et al[9] | Calviño et al[11] | Rubino et al[16] |
Number | 417 | 218 | 208 | 78 | 118 |
Sex (male/female) | 240/177 | 140/88 | 116/92 | 42/36 | 66/52 |
Age (mo, yr) | 8 mo-87 yr | 2 yr 4 mo-13 yr | 9 mo-15 yr | 1 yr-13 yr | 1 yr-17 yr |
Median age | 7.5 ry | - | 6.4 yr | 5.5 yr | 7 yr |
Etiologic factor | - | - | - | - | - |
Infections | 38 | 53 | - | 28 | - |
Drug intake | 18.50 | - | - | 18.00 | - |
Allergy | - | 21.10 | - | - | - |
Abdominal pain as initial manifestation | 13.70 | 16.00 | 58.00 | 16.70 | - |
Time between abdominal pain and purpura (d) | 6-15 d | 1-12 d | 1-13 d | 1-10 d | - |
Median d | 10 | - | 4.8 | 3.3 d | - |
Use of glucocorticoid | - | - | 7.5 ± 2.8 | - | - |
No use of glucocorticoid | - | - | 10.2 ± 3.6 | - | - |
Leukocytosis was present | 36.7 | 46.8 | 47.5 | 52.6 | - |
Anemia | 8.9 | 11.5 | 10.5 | 7.7 | 10 |
ESR was present | 80.1 | 16.5 | - | 63.9 | 40 |
Increased IgA serum | 31.7 | - | - | 57.1 | 27 |
ANCAs | 0 | - | - | - | - |
Stool occult blood | - | 16.10% | 52/160 positive | 12 positive cases | 30 positive cases |
CT or X-ray | - | - | 42/82 positive | 18/21 positive | |
Gastroscopy | - | - | 15/27 positive | 2/2 positive | 3/5 positive |
Treatment | - | - | - | - | - |
Corticosteroids | 35 | 90 | 99.50 | 23.10 | 68 |
Cytotoxic drugs | 5 | Use for some patients with renal impairment (87 patients) | - | Use for two children due to severe renal impairment | Use for one chid for steroid resistance |
Nonsteroidal anti-inflammatory drugs | 14 | - | - | - | 43 |
Dialysis | 1 | - | - | - | - |
Outcome | - | - | - | - | |
Complete resolution | 83.20 | - | - | 88.40 | - |
- | - | - | 100 | ||
Persistent nephropathy (renal sequelae) | 7.70 | - | - | 11.60 | - |
Reoccurrence | 31.90 | - | 10.10 | 14.50 | 21.00 |
The child presented some specific clinical manifestations. First, gastrointestinal symptoms are reported in 50%–85% of HSP patients, commonly including nausea and vomiting, vomiting blood, bloody stool, and melena. Other rare gastrointestinal symptoms include intussusception, mesenteric ischemia, intestinal perforation, massive gastrointestinal bleeding, acute non-calculous cholecystitis, hemorrhagic ascites with peritonitis, pancreatitis, and biliary cirrhosis[11-16], but an association with chronic gastrointestinal diseases is rarely reported[17,18]. The patient in our study presented with abdominal pain and peritonitis in the early stage, associated with underlying chronic non-atrophic gastritis and erosive duodenitis, a complicated condition reported here for the first time based on our literature review.
Second, skin symptoms in HSP patients usually precede gastrointestinal symptoms, although the opposite occurs in 12%–19% of patients[4]. In a study including 208 HSP patients, Chen et al[14] found that 41 patients (25.3%) presented with gastrointestinal symptoms before the appearance of skin lesions, with an average interval of 4.8 d, while 18 patients had abdominal pain more than 1 wk before the skin symptoms[15]. The patient in the present report had abdominal pain that lasted for 19 d before the purpuric rash appeared at the typical site. Currently the longest interval between rash and abdominal pain (rash appearance first) in HSP patients is 75 d, but this patient was diagnosed with pancreatitis at an early stage, thus not excluding that early abdominal pain could have been caused by pancreatitis[10]. According to the literature we searched, the interval in most patients was 2–10 d[5,19]. With the exception of the present report, the longest interval was 12 d and the shortest interval was 1 d[7,8]. Our patient sustained rash onset after 19 d of abdominal pain, the longest interval reported to date.
Treatment with glucocorticoids and antibiotics in another hospital failed to control the disease. After admission to our hospital, CRP (an inflammation indicator) increased progressively, and abdominal pain was significantly relieved after intensive anti-infection treatment. Thus, the poor effect of glucocorticoids might be related to the failure of infection control. In our case, it is possible that a gastrointestinal infection triggered HSP. In fact, HSP commonly occurs after bacterial or viral infections (usually upper respiratory tract or intestinal infections), especially during the autumn season. Therefore, infection may play a role in the etiology of IgA vasculitis. The following hypotheses are proposed[20]: (1) The N-Acetylgalactosamine (GalNAc) present on the surface of the pathogen may contribute to the production of IgA and IgG antibodies that cross-react with Galactose deficient immunoglobulin A1 (Gd-IgA1); (2) Microbes may contain antigenic structures like the vascular wall, leading to the production of cross-reactive autoantibodies; (3) Mucosal infections result in upregulation of IL-6, which may contribute to the development of Gd-IgA1 by altering the glycosylation mechanism.
Currently, glucocorticoids are considered effective for HSP gastrointestinal and joint symptoms, and early initiation can effectively relieve abdominal and joint symptoms, significantly relieve abdominal pain, improve the relief rate within 24 h, as well as reducing the risk of intussusception and intestinal bleeding[19,21-25]. There is no evidence to prove that glucocorticoid therapy is effective in the regression and recurrence of rash[26], but we guess that early use of glucocorticoids may be associated with delayed appearance of rash in HSP. The patient in the present study was treated out of hospital with hydrocortisone, 5 mg/kg/d for 6 d, which may be an important reason for the delayed rash.
HSP is a relatively common childhood disorder that may be difficult to diagnose when the typical signs of rash, abdominal pain, arthralgias, and nephritis do not occur simultaneously. Our case serve as a reminder that abdominal pain can appear long before the rash.
Provenance and peer review: Unsolicited article; Externally peer reviewed.
Peer-review model: Single blind
Specialty type: Gastroenterology and hepatology
Country/Territory of origin: China
Peer-review report’s scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): B, B
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0
P-Reviewer: Baryshnikova NV, Russia; Ghannam WM, Egypt S-Editor: Liu JH L-Editor: A P-Editor: Liu JH
1. | Kawasaki Y, Ono A, Ohara S, Suzuki Y, Suyama K, Suzuki J, Hosoya M. Henoch-Schönlein purpura nephritis in childhood: pathogenesis, prognostic factors and treatment. Fukushima J Med Sci. 2013;59:15-26. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 36] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis (0)] |
2. | Kanik A, Kose E, Baran M, Kose SS, Eliacik K, Sayan A, Helvaci M, Aksu N. Henoch-Schönlein purpura in two pediatric patients presenting as terminal ileitis. Dig Dis Sci. 2015;60:269-271. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis (0)] |
3. | Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, Buoncompagni A, Lazar C, Bilge I, Uziel Y, Rigante D, Cantarini L, Hilario MO, Silva CA, Alegria M, Norambuena X, Belot A, Berkun Y, Estrella AI, Olivieri AN, Alpigiani MG, Rumba I, Sztajnbok F, Tambic-Bukovac L, Breda L, Al-Mayouf S, Mihaylova D, Chasnyk V, Sengler C, Klein-Gitelman M, Djeddi D, Nuno L, Pruunsild C, Brunner J, Kondi A, Pagava K, Pederzoli S, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO). EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis. 2010;69:798-806. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 817] [Cited by in F6Publishing: 803] [Article Influence: 57.4] [Reference Citation Analysis (0)] |
4. | Saulsbury FT. Clinical update: Henoch-Schönlein purpura. Lancet. 2007;369:976-978. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 188] [Cited by in F6Publishing: 165] [Article Influence: 9.7] [Reference Citation Analysis (0)] |
5. | Calvo-Río V, Loricera J, Mata C, Martín L, Ortiz-Sanjuán F, Alvarez L, González-Vela MC, González-Lamuño D, Rueda-Gotor J, Fernández-Llaca H, González-López MA, Armesto S, Peiró E, Arias M, González-Gay MA, Blanco R. Henoch-Schönlein purpura in northern Spain: clinical spectrum of the disease in 417 patients from a single center. Medicine (Baltimore). 2014;93:106-113. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 106] [Cited by in F6Publishing: 93] [Article Influence: 9.3] [Reference Citation Analysis (0)] |
6. | Fan GZ, Li RX, Jiang Q, Niu MM, Qiu Z, Chen WX, Liu HH, Ruan JW, Hu P. Streptococcal infection in childhood Henoch-Schönlein purpura: a 5-year retrospective study from a single tertiary medical center in China, 2015-2019. Pediatr Rheumatol Online J. 2021;19:79. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
7. | Dinler G, Bek K, Açikgöz Y, Kalayci AG. Acute pancreatitis as a presenting feature of Henoch-Schönlein purpura. Turk J Pediatr. 2010;52:191-193. [PubMed] [Cited in This Article: ] |
8. | Frigui M, Lehiani D, Koubaa M, Bouaziz Z, Abid B, Beyrouti I, Mnif Z, Bahloul Z, Jemaa MB. Acute pancreatitis as initial manifestation of adult Henoch-Schönlein purpura: report of a case and review of literature. Eur J Gastroenterol Hepatol. 2011;23:189-192. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
9. | Chao HC, Kong MS, Lin SJ, Huang JL. Gastrointestinal manifestation and outcome of Henoch-Schonlein purpura in children. Chang Gung Med J. 2000;23:135-141. [PubMed] [Cited in This Article: ] |
10. | Sato S, Irisawa A, Shio K, Takagi T, Ohira H. Case of an elderly man with associated Henoch-Schönlein purpura during treatment of acute pancreatitis. Fukushima J Med Sci. 2006;52:135-142. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis (0)] |
11. | Calviño MC, Llorca J, García-Porrúa C, Fernández-Iglesias JL, Rodriguez-Ledo P, González-Gay MA. Henoch-Schönlein purpura in children from northwestern Spain: a 20-year epidemiologic and clinical study. Medicine (Baltimore). 2001;80:279-290. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 199] [Cited by in F6Publishing: 169] [Article Influence: 7.3] [Reference Citation Analysis (0)] |
12. | Sohagia AB, Gunturu SG, Tong TR, Hertan HI. Henoch-schonlein purpura-a case report and review of the literature. Gastroenterol Res Pract. 2010;2010:597648. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 42] [Cited by in F6Publishing: 52] [Article Influence: 3.7] [Reference Citation Analysis (0)] |
13. | Jeong YK, Ha HK, Yoon CH, Gong G, Kim PN, Lee MG, Min YI, Auh YH. Gastrointestinal involvement in Henoch-Schönlein syndrome: CT findings. AJR Am J Roentgenol. 1997;168:965-968. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 2.5] [Reference Citation Analysis (0)] |
14. | Chen MJ, Chu CH, Lin SC, Shih SC, Wang TE. Eosinophilic gastroenteritis: clinical experience with 15 patients. World J Gastroenterol. 2003;9:2813-2816. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 131] [Cited by in F6Publishing: 131] [Article Influence: 6.2] [Reference Citation Analysis (0)] |
15. | Fan Z, Tian X, Pan J, Li Y, Zhang Y, Jing H. Terminal ileitis induced by Henoch-Schonlein purpura that presented as acute appendicitis: a case report. Medicine (Baltimore). 2015;94:e492. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis (0)] |
16. | Rubino C, Monacelli C, Marrani E, Paci M, Indolfi G, Simonini G, Trapani S. Gastrointestinal involvement in IgA vasculitis: a single-center 11-year study on a cohort of 118 children. Clin Rheumatol. 2021;40:5041-5046. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis (0)] |
17. | Lerkvaleekul B, Treepongkaruna S, Saisawat P, Thanachatchairattana P, Angkathunyakul N, Ruangwattanapaisarn N, Vilaiyuk S. Henoch-Schönlein purpura from vasculitis to intestinal perforation: A case report and literature review. World J Gastroenterol. 2016;22:6089-6094. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
18. | Rubino C, Paci M, Resti M, Lionetti P, Trapani S. Late Relapse of Henoch-Schönlein Purpura in an Adolescent Presenting as Severe Gastroduodenitis. Front Pediatr. 2018;6:355. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis (0)] |
19. | Ji C. Clinical analysis of 218 children with Henoch-Schonlein purpura. Linchuang erke Zazhi. 2008;26:961-963. [Cited in This Article: ] |
20. | Heineke MH, Ballering AV, Jamin A, Ben Mkaddem S, Monteiro RC, Van Egmond M. New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura). Autoimmun Rev. 2017;16:1246-1253. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 155] [Cited by in F6Publishing: 198] [Article Influence: 28.3] [Reference Citation Analysis (0)] |
21. | Reinehr T, Bürk G, Andler W. Does steroid treatment of abdominal pain prevent renal involvement in Henoch-Schönlein purpura? J Pediatr Gastroenterol Nutr. 2000;31:323-324. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
22. | Weiss PF, Klink AJ, Localio R, Hall M, Hexem K, Burnham JM, Keren R, Feudtner C. Corticosteroids may improve clinical outcomes during hospitalization for Henoch-Schönlein purpura. Pediatrics. 2010;126:674-681. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 3.8] [Reference Citation Analysis (0)] |
23. | Weiss PF, Feinstein JA, Luan X, Burnham JM, Feudtner C. Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review. Pediatrics. 2007;120:1079-1087. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 151] [Cited by in F6Publishing: 122] [Article Influence: 7.2] [Reference Citation Analysis (0)] |
24. | Huber AM, King J, McLaine P, Klassen T, Pothos M. A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein Purpura [ISRCTN85109383]. BMC Med. 2004;2:7. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 124] [Cited by in F6Publishing: 90] [Article Influence: 4.5] [Reference Citation Analysis (0)] |
25. | Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Hölttä T, Jahnukainen T, Rajantie J, Ormälä T, Nuutinen M. Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective study. Arch Dis Child. 2010;95:871-876. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 6.3] [Reference Citation Analysis (0)] |
26. | Sunderkötter C, Bonsmann G, Sindrilaru A, Luger T. Management of leukocytoclastic vasculitis. J Dermatolog Treat. 2005;16:193-206. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 3.2] [Reference Citation Analysis (0)] |